Patents by Inventor Michael Ankersen

Michael Ankersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds with growth hormone releasing properties
    Patent number: 6274584
    Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. The peptides have the formula (1): wherein a, b, A, R1, L1, D, R3, R4, R2, L2, E and G are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation, and hence, improved bioavailability.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: August 14, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Michael Ankersen, Thomas Kruse Hansen, Henning Thøgersen
  • Use of somatostatin agonists and antagonists for treating diseases related to the eye
    Patent number: 6159941
    Abstract: The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of the general formula Ia or Ib ##STR1## or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4 and, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions are high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: December 12, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Michael Ankersen, Carsten Enggaard Stidsen, Michael Albert Crider
  • Compounds with growth hormone releasing properties
    Patent number: 6127354
    Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. The peptides have the formula (I): ##STR1## wherein a, b, A, R.sup.1, L.sup.1, D, R.sup.3, R.sup.4, R.sup.2, L.sup.2, E and G are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation, and hence, improved bioavailability.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: October 3, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Michael Ankersen, Thomas Kruse Hansen, Henning Th.o slashed.gersen
  • Somatostatin agonists and antagonists
    Patent number: 6127343
    Abstract: The present invention relates to compounds, compositions containing them, and their use for treating medical disorders related to binding to human somatostatin receptor subtypes.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: October 3, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Michael Ankersen, Carsten Enggaard Sitdsen, Henrik Sune Andersen
  • Compounds with growth hormone releasing properties
    Patent number: 6127341
    Abstract: Compounds of the general formula I ##STR1## compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are described.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: October 3, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse Hansen, Jesper Lau, Bernd Peschke, Michael Ankersen, Kjeld Madsen, Nils Langeland Johansen
  • Compounds with growth hormone releasing properties
    Patent number: 6127391
    Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: October 3, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse Hansen, Bernd Peschke, Jesper Lau, Behrend Friedrich Lundt, Michael Ankersen, Brett Watson, Kjeld Madsen
  • Constrained somatostatin agonists and antagonists
    Patent number: 6083960
    Abstract: The present invention relates to a compound of general formula I ##STR1## for treating medical disorders related to binding to human somatostatin receptor subtypes.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: July 4, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Michael Ankersen, Florenzio Zaragoza Dorwald, Carsten Enggaard Stidsen, Albert Michael Crider
  • Compounds with growth hormone releasing properties
    Patent number: 6083908
    Abstract: Compounds of Formula I ##STR1## and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed, wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.4a, R.sup.5a, G, J and D are as defined in the specification.
    Type: Grant
    Filed: January 12, 1999
    Date of Patent: July 4, 2000
    Assignee: Novo Nordisk A/S
    Inventor: Michael Ankersen
  • Constrained somatostatin agonists and antagonists
    Patent number: 6020349
    Abstract: The present invention relates to a compound of general formula I ##STR1## for treating medical disorders related to binding to human somatostatin receptor subtypes.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: February 1, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Michael Ankersen, Florenzio Zaragoza Dorwald, Carsten Enggaard Stidsen, Albert Michael Crider
  • Compounds with growth hormone releasing properties
    Patent number: 6013658
    Abstract: There are disclosed novel synthetic peptides of formula (I) ##STR1## where A, B, D, E, F, G, J, m, n, and p are defined in the specification. Compounds of formula (I) promote the release of growth hormone in humans and animals. Growth promoting compositions containing such compounds of formula (I) as the active ingredient, methods of stimulating the release of growth hormone, and the use of such compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: January 11, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Bernd Peschke, Thomas Kruse Hansen, Nils Langeland Johansen, Michael Ankersen
  • Compounds with growth hormone releasing properties
    Patent number: 5977178
    Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: November 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse Hansen, Bernd Peschke, Jesper Lau, Behrend Friedrich Lundt, Michael Ankersen, Brett Watson, Kjeld Madsen
  • Compounds with growth hormone releasing properties
    Patent number: 5922770
    Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. The peptides have the formula (I): ##STR1## wherein a, b, A, R.sup.1, L.sup.1, D, R.sup.3, R.sup.4, R.sup.2, L.sup.2, E and G are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation, and hence, improved bioavailability.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: July 13, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Michael Ankersen, Thomas Kruse Hansen, Henning Th.o slashed.gersen